Financial Shenanigans

The Forensic Verdict

Olectra screens as Elevated forensic risk, with a score of 58/100. The two issues that matter are the sheer affiliated-party route to market, with FY2025 related-party sale and service values around ₹1,425.1 crore, and cash conversion that depends heavily on payables while free cash flow remains weak. The cleanest offset is that FY2025 was not an audit-control story: the latest annual report says the statutory audit had no qualifications, no auditor-reported fraud, and no current-year auditor resignation. The data point that would most change the grade is FY2026 cash collection from Evey/SPV-linked receivables without another trade-payables expansion.

Breeding Ground

The breeding ground amplifies the accounting risks because Olectra combines promoter control, large affiliated sales channels, and an order-book narrative that depends on SPV execution. This is not offset by an auditor-control problem in FY2025, but the governance structure makes cash collection and related-party economics central diligence items.

Earnings Quality

Reported earnings look real enough at the income-statement level, but the balance-sheet plumbing is too affiliated and working-capital heavy to call earnings high quality. The clean side is that FY2025 revenue growth outpaced receivables growth; the uncomfortable side is that a large share of sales moves through Evey/MEIL-linked entities.

FY2025 revenue grew 56.2%, while trade receivables grew 35.1%, so the simple early-revenue screen is not red on the latest year. That said, receivables were still ₹693.5 crore, debtor days were still 140, and management has acknowledged that subsidy and SPV payment mechanics can create collection lags.

The one-time-income test is mostly clean after FY2020. Other income was only ₹14.0 crore in FY2025 versus operating income of ₹262.0 crore, and exceptional items were nil; associate profit was ₹3.4 crore, useful but not large enough to explain the year.

The expense-shifting screen is yellow, not red. FY2025 capex was ₹177.0 crore, depreciation was ₹37.3 crore, and CWIP reached ₹186.9 crore as the new EV facility was built; that is plausible growth investment, but useful lives, capitalization cutoffs, and related-party construction costs should be re-tested once the factory is fully operational.

Cash Flow Quality

Cash flow quality is the biggest accounting risk because FY2025 operating cash flow was supported by supplier credit while free cash flow stayed negative. A company can earn real accounting profit and still be a weak cash compounder if growth is financed by payables, inventory, and SPV receivables.

The three-year CFO-to-net-income ratio is a respectable 0.96x, but the three-year FCF-to-net-income ratio is negative 0.16x. FY2025 itself illustrates the split: operating cash flow roughly matched net income, yet free cash flow was negative after the greenfield capex step-up.

FY2025 trade payables added ₹277.0 crore to cash from operations, more than the full reported CFO of ₹140.7 crore. That support did not repeat in H1 FY2026, when operating cash flow was negative ₹31.0 crore as inventory rose ₹119.4 crore and other financial assets absorbed cash; this is the clearest cash-flow shenanigan risk even without evidence of factoring or supplier-finance presentation.

Metric Hygiene

Management’s adjusted EBITDA definition is transparent, but the order book and working-capital metrics need heavier forensic haircuts than headline presentations imply. The central test is whether order book converts into arm-length cash from non-stretched counterparties.

The weakest metric is order book, not adjusted EBITDA. In February 2026, public market updates described a new ₹1,800 crore TGSRTC-related order where EVEY would procure buses from Olectra and the transactions would be related-party and arm length; that structure can be commercially normal in this sector, but it makes the cash bridge more important than the award value. The delivery-history record also supports a haircut: prior volume targets were reset repeatedly before FY2026 management shifted to more conditional language.

What to Underwrite Next

The next underwriting work should focus on cash conversion, related-party aging, and whether the greenfield factory starts producing depreciation-backed revenue rather than more capitalized cost. These are the items most likely to move the forensic grade.

This forensic work should affect valuation and position sizing, not break the thesis by itself. Olectra has real revenue growth, visible demand, and clean current audit language, but the accounting risk is not a footnote because affiliated counterparties and working-capital funding drive the quality of reported growth. The appropriate treatment is a valuation haircut and a higher required margin of safety until FY2026 proves that profit can convert to free cash flow without payable expansion.